Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Q-1802 in advanced solid tumors
NCT04856150Phase 1Unknown
- Sponsor
- QureBio Ltd.
- Start
- May 2021
- Primary completion
- Apr 2024
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of q-1802 in solid tumor (advanced stage), sponsored by QureBio Ltd. Primary endpoint: Number of participants with dose limiting toxicities at 28 days. Status: unknown.
02
Drugs
q-1802
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04856150.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04856150.